Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nathalie Charland

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
Microbiology (Reading, England)|December 5, 1997
Characterization and protective activity of a monoclonal antibody against a capsular epitope shared by Streptococcus suis serotypes 1, 2 and 1/2Nathalie Charland, Mario Jacques, Sonia Lacouture, et al.
Scientific Reports|April 26, 2018
Assessing the benefits of early pandemic influenza vaccine availability: a case study for Ontario, CanadaDavid Champredon, Marek Laskowski, Nathalie Charland, et al.
Microbiology (Reading, England)|March 11, 1998
Streptococcus suis serotype 2 mutants deficient in capsular expressionNathalie Charland, Josée Harel, Marylène Kobisch, et al.
Human Vaccines & Immunotherapeutics|December 19, 2017
The establishment of surrogates and correlates of protection: Useful tools for the licensure of effective influenza vaccines?Brian J Ward, Stephane Pillet, Nathalie Charland, et al.
Infection and Immunity|August 17, 2002
Protection from group B streptococcal infection in neonatal mice by maternal immunization with recombinant Sip proteinDenis Martin, Stéphane Rioux, Edith Gagnon, et al.
Infection and Immunity|April 23, 2004
Prevention of pneumococcal disease in mice immunized with conserved surface-accessible proteinsJosée Hamel, Nathalie Charland, Isabelle Pineau, et al.
Vaccine|April 9, 2017
Plant-made virus-like particle vaccines bearing the hemagglutinin of either seasonal (H1) or avian (H5) influenza have distinct patterns of interaction with human immune cells in vitroHilary E Hendin, Stéphane Pillet, Amanda N Lara, et al.
Plant Biotechnology Journal|March 5, 2010
The production of hemagglutinin-based virus-like particles in plants: a rapid, efficient and safe response to pandemic influenzaMarc-André D'Aoust, Manon M-J Couture, Nathalie Charland, et al.
Vaccine|November 19, 2018
Characterization of the innate stimulatory capacity of plant-derived virus-like particles bearing influenza hemagglutininSo-Yoon Won, Kristin Hunt, Hannah Guak, et al.
Human Vaccines & Immunotherapeutics|July 2, 2021
Projected impact of a plant-derived vaccine on the burden of seasonal influenza in CanadaLauren Ramjee, William Lemay, Nesrin Vurgun, et al.
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
Microbiology (Reading, England)|December 5, 1997
Characterization and protective activity of a monoclonal antibody against a capsular epitope shared by Streptococcus suis serotypes 1, 2 and 1/2Nathalie Charland, Mario Jacques, Sonia Lacouture, et al.
Scientific Reports|April 26, 2018
Assessing the benefits of early pandemic influenza vaccine availability: a case study for Ontario, CanadaDavid Champredon, Marek Laskowski, Nathalie Charland, et al.
Microbiology (Reading, England)|March 11, 1998
Streptococcus suis serotype 2 mutants deficient in capsular expressionNathalie Charland, Josée Harel, Marylène Kobisch, et al.
Human Vaccines & Immunotherapeutics|December 19, 2017
The establishment of surrogates and correlates of protection: Useful tools for the licensure of effective influenza vaccines?Brian J Ward, Stephane Pillet, Nathalie Charland, et al.
Infection and Immunity|August 17, 2002
Protection from group B streptococcal infection in neonatal mice by maternal immunization with recombinant Sip proteinDenis Martin, Stéphane Rioux, Edith Gagnon, et al.
Infection and Immunity|April 23, 2004
Prevention of pneumococcal disease in mice immunized with conserved surface-accessible proteinsJosée Hamel, Nathalie Charland, Isabelle Pineau, et al.
Vaccine|April 9, 2017
Plant-made virus-like particle vaccines bearing the hemagglutinin of either seasonal (H1) or avian (H5) influenza have distinct patterns of interaction with human immune cells in vitroHilary E Hendin, Stéphane Pillet, Amanda N Lara, et al.
Plant Biotechnology Journal|March 5, 2010
The production of hemagglutinin-based virus-like particles in plants: a rapid, efficient and safe response to pandemic influenzaMarc-André D'Aoust, Manon M-J Couture, Nathalie Charland, et al.
Vaccine|November 19, 2018
Characterization of the innate stimulatory capacity of plant-derived virus-like particles bearing influenza hemagglutininSo-Yoon Won, Kristin Hunt, Hannah Guak, et al.
Human Vaccines & Immunotherapeutics|July 2, 2021
Projected impact of a plant-derived vaccine on the burden of seasonal influenza in CanadaLauren Ramjee, William Lemay, Nesrin Vurgun, et al.
Pageof 2